FIIs invest over ₹20,000 crore in four days as markets rise for fifth straight session

Foreign institutional investors (FIIs) extended their buying streak in Indian equities to a fourth consecutive session on Wednesday, November 4, purchasing shares worth a net ₹7,284.03 crore, according to provisional exchange data.

FIIs bought equities worth ₹21,607.38 crore and sold shares worth ₹14,323.35 crore during the session.

Domestic institutional investors (DIIs), meanwhile, remained net sellers for the second consecutive session. They sold shares worth ₹20,105.05 crore and bought equities worth ₹16,392.82 crore, resulting in net outflows of ₹3,712.23 crore.

On Tuesday, November 3, FIIs were net buyers to the tune of ₹6,836.81 crore, while DIIs recorded net sales of ₹3,678.85 crore. FIIs had bought shares worth ₹20,970.51 crore and sold ₹14,133.70 crore, while DIIs bought equities worth ₹16,723.91 crore and sold ₹20,402.76 crore.

The development came as Indian equity benchmarks extended their winning streak to a fifth consecutive session on Wednesday, with the Nifty gaining over 5% in five days — its biggest such rise in seven months. The index closed at a two-month high, reclaiming the 23,900 mark, while the Sensex ended above 77,300. The Nifty's five-session gaining streak is its longest since June 2026.

The Sensex rose 384 points to close at 77,301, while the Nifty gained 150 points to settle at 23,961. The Nifty Bank advanced 374 points to 55,914, and the Nifty Midcap index added 909 points to end at 59,505.

Reliance Industries saw a sharp recovery in the final hour of trade and ended higher. HDFC Bank and FMCG stocks also supported the benchmarks. However, IT stocks remained under pressure, with the Nifty IT index declining 1.5%.

Among individual stocks, Alembic Pharmaceuticals surged nearly 13% after reporting strong Q2 results. Redington, Indo Count, HEG, Fractal and Emcure also gained nearly 10% each following their quarterly results. NLC India rose over 7% on its Q2 results and the offer for sale in its subsidiary's IPO.

Biocon pared gains to end with marginal advances following subdued Q2 results. Capital market stocks saw profit booking, with BSE closing 2% lower ahead of its Q2 results. V2 Retail fell nearly 10% after cutting its same-store sales growth guidance to 5% from 8-10%.

Market breadth remained firmly positive, with the advance-decline ratio at 3:1.

Also Read: FIIs extend cash market buying streak to third straight day, pump in over ₹13,500 crore